Standard BioTools

South San Francisco

Total Offices: 13

944 Total Employees

View Website

What's It Like to Work at Standard BioTools?

Updated on September 09, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Standard BioTools and has not been reviewed or approved by Standard BioTools.

What's it like to work at Standard BioTools?

Strengths in mission‑driven science and differentiated tools, reinforced by a streamlined focus and balance‑sheet reset, are accompanied by multi‑year restructuring, site shifts, and workload pressures. Together these dynamics suggest an environment attractive to those comfortable with turnarounds and broader scopes, while presenting higher uncertainty for those prioritizing stability.

Key Insight for Candidates

Defining pattern: compelling science set against serial post‑deal restructurings (including R&D consolidation to Singapore). Turnaround‑driven cost discipline creates volatility, heavier workloads, and fuzzy career paths. Good for change‑tolerant candidates; risky if you seek stability.

Evidence in Action

Serial Restructuring Cadence — April 2024 'workforce reduction' (~10%) and a 2025 'global reduction‑in‑force' (~15%) with R&D consolidation to Singapore are documented organizational actions. Employees experience job‑security anxiety, leaner teams, and shifting scopes, shaping reputation as a high‑change workplace.
M&A Portfolio Resets — The January 30, 2026 SomaLogic divestiture to Illumina ($350M upfront, up to $75M earn‑outs) and 'continuing operations' focus are repeatedly communicated strategy levers. Employees see roadmap resets and process changes alongside a strengthened cash runway, influencing perceived stability and investment confidence.

Positive Themes About Standard BioTools

Mission & Purpose: Work centers on mass cytometry, imaging, and microfluidics that enable translational oncology and immunology research, which many find meaningful. Company and investor materials position these as flagship tools advancing impactful science.
Innovation & Products: Specialized platforms like CyTOF and Imaging Mass Cytometry are highlighted as niche but influential tools in multi‑omics and spatial biology. The portfolio offers technically challenging work with real research impact.
Market Position & Stability: Recent portfolio moves, including divesting SomaLogic to Illumina, left the company leaner and better capitalized to focus on its tools franchise. Disclosures also cite operationalized cost savings supporting a turnaround focus.

Considerations About Standard BioTools

Job Insecurity: Workforce reductions across 2024–2025 and site consolidations indicate elevated role risk. R&D relocation from South San Francisco to Singapore and related exits underscore ongoing changes that can affect positions.
Change Fatigue: Serial restructurings, merger‑and‑then‑divestiture activity, and shifting org charts point to a high‑change environment. Company updates emphasize cost cutting and a profitability focus amid choppy revenue, which can disrupt planning rhythms.
Workload & Burnout: Heavier individual workloads during transitions are noted amid reductions and site changes. Lean teams and consolidation can expand scope per person and increase day‑to‑day strain.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.